Astellas Drug Patent Portfolio

Astellas owns 12 orange book drugs protected by 66 US patents with Adenoscan having the least patent protection, holding only 1 patent. And Lexiscan with maximum patent protection, holding 19 patents. Given below is the list of Astellas's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10786500 Stable pharmaceutical composition for oral administration 01 Jul, 2036
Active
US11938130 Stable pharmaceutical composition for oral administration 01 Jul, 2036
Active
US11938131 Stable pharmaceutical composition for oral administration 01 Jul, 2036
Active
US11938132 Stable pharmaceutical composition for oral administration 01 Jul, 2036
Active
US11938133 Stable pharmaceutical composition for oral administration 01 Jul, 2036
Active
US11944620 Stable pharmaceutical composition for oral administration 01 Jul, 2036
Active
US11273171 Methods for treating or preventing ophthalmological conditions 11 Jul, 2034
Active
US11491176 Methods for treating or preventing ophthalmological conditions 11 Jul, 2034
Active
US12016875 Methods for treating or preventing ophthalmological conditions 11 Jul, 2034
Active
US10836768 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists 28 Mar, 2034
Active
US9422299 Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists 28 Mar, 2034
Active
US9987274 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists 28 Mar, 2034
Active
US11839689 Formulations of enzalutamide 11 Sep, 2033
Active
US8969336 Diamino heterocyclic carboxamide compound 28 Nov, 2032
Active
US9918970 Pharmaceutical composition comprising solifenacin 18 May, 2031
Active
US8871761 NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders 04 Apr, 2031
Active
US9487491 Diamino heterocyclic carboxamide compound 28 Jul, 2030
Active
US10206879 Active ingredient containing stabilised solid forms and method for the production thereof 14 Mar, 2028
Active
US10603280 Active ingredient containing stabilised solid medicinal forms and methods for the production thereof 14 Mar, 2028
Active
US10206879 Active ingredient containing stabilised solid forms and method for the production thereof 14 Sep, 2027
Active
US10603280 Active ingredient containing stabilised solid medicinal forms and methods for the production thereof 14 Sep, 2027
Active
US7709517 Diarylhydantoin compounds 13 Aug, 2027
Active
US8106183 Process for preparing an A2A-adenosine receptor agonist and its polymorphs 02 Feb, 2027
Active
US9085601 Process for preparing an A2A-adenosine receptor agonist and its polymorphs 02 Feb, 2027
Active
USRE47301 Process for preparing an A2A-adenosine receptor agonist and its polymorphs 02 Feb, 2027
Active
US8236773 Aptamer therapeutics useful in the treatment of complement-related disorders 11 Nov, 2026
Active
US8183274 Treatment of hyperproliferative disorders with diarylhydantoin compounds 24 Aug, 2026
Active
US9126941 Treatment of hyperproliferative disorders with diarylhydantoin compounds 15 May, 2026
Active
US6812238 N-substituted carbamoyloxyalkyl-azolium derivatives 01 May, 2026
Active
US10812238 Configurable reference signals 31 Oct, 2025
Active
US6812238 N-substituted carbamoyloxyalkyl-azolium derivatives 31 Oct, 2025
Active
US10947544 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
Active
US7538211 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
Active
US7579456 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
Active
US7803931 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
Active
US9617546 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
Active
US6403567 N-pyrazole A2A adenosine receptor agonists 10 Apr, 2022 Expired
US6774104 Stabilized pharmaceutical composition in lyophilized form 08 Jul, 2021 Expired
US6774104 Stabilized pharmaceutical composition in lyophilized form 08 Jan, 2021 Expired
US7459561 N-substituted carbamoyloxyalkyl-azolium derivatives 31 Oct, 2020 Expired
US6642210 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists 22 Jun, 2019 Expired
US7144872 N-pyrazole A2A receptor agonists 22 Jun, 2019 Expired
US7183264 N-pyrazole A2A receptor agonists 22 Jun, 2019 Expired
US7582617 Myocardial perfusion imaging method 22 Jun, 2019 Expired
US7655636 Use of A2A adenosine receptor agonists 22 Jun, 2019 Expired
US7655637 N-pyrazole A2A receptor agonists 22 Jun, 2019 Expired
US7683037 Myocardial perfusion imaging method 22 Jun, 2019 Expired
US8106029 Use of A2A adenosine receptor agonists 22 Jun, 2019 Expired
US8133879 Myocardial perfusion imaging methods and compositions 22 Jun, 2019 Expired
US8183226 Myocardial perfusion imaging method 22 Jun, 2019 Expired
US8470801 Myocardial perfusion imaging methods and compositions 22 Jun, 2019 Expired
US8536150 Methods of myocardial perfusion imaging 22 Jun, 2019 Expired
US9045519 N-pyrazole A2A receptor agonists 22 Jun, 2019 Expired
US9289446 Myocardial perfusion imaging methods and compositions 22 Jun, 2019 Expired
USRE47351 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists 22 Jun, 2019 Expired
US6017927 Quinuclidine derivatives and medicinal composition thereof 19 May, 2019 Expired
US6440458 Sustained release preparations 25 Mar, 2019 Expired
US6576259 Sustained release formulations containing tacrolimus 25 Mar, 2019 Expired
US6884433 Sustained release formulation containing tacrolimus 25 Mar, 2019 Expired
US8551522 Sustained-release formulation 25 Mar, 2019 Expired
US6107458 Cyclic hexapeptides having antibiotic activity 16 Mar, 2019 Expired
US6017927 Quinuclidine derivatives and medicinal composition thereof 19 Nov, 2018 Expired
US5965156 Amphotericin B liposome preparation 12 Oct, 2016 Expired
US5874104 Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics 23 Feb, 2016 Expired
US6265536 Cyclic hexapeptides having antibiotic activity 29 Sep, 2015 Expired
US5731296 Selective vasodilation by continuous adenosine infusion 24 Mar, 2015 Expired


Given below is the list of recent legal activities going on the following drug patents of Astellas.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 17 May, 2024 US10836768
Payment of Maintenance Fee, 8th Year, Large Entity 24 Apr, 2024 US9487491
Payment of Maintenance Fee, 4th Year, Large Entity 09 Apr, 2024 US10812238
Recordation of Patent eGrant 02 Apr, 2024 US11944620
Recordation of Patent Grant Mailed 02 Apr, 2024 US11944620
Patent Issue Date Used in PTA Calculation 02 Apr, 2024 US11944620
Mail Patent eGrant Notification 02 Apr, 2024 US11944620
Email Notification 02 Apr, 2024 US11944620
Patent eGrant Notification 02 Apr, 2024 US11944620
Payment of Maintenance Fee, 4th Year, Large Entity 29 Mar, 2024 US10786500
Patent eGrant Notification 26 Mar, 2024 US11938133
Initial letter Re: PTE Application to regulating agency 26 Mar, 2024 US8236773
Recordation of Patent eGrant 26 Mar, 2024 US11938133
Email Notification 26 Mar, 2024 US11938131
Initial letter Re: PTE Application to regulating agency 26 Mar, 2024 US9617546


Astellas Drug Patents' Oppositions Filed in EPO

Astellas drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 03, 2010, by Basilea Pharmaceutica International Ag. This opposition was filed on patent number EP07802308A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11184401A Dec, 2015 Generics (U.K.) Limited Revoked
EP06748863A Oct, 2012 Fickert, Stefan Patent maintained as amended
EP07802308A Dec, 2010 Basilea Pharmaceutica International AG Patent maintained as amended


Astellas's Family Patents

Astellas drugs have patent protection in a total of 36 countries. It's US patent count contributes only to 18.2% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Astellas Drug List

Given below is the complete list of Astellas's drugs and the patents protecting them.


1. Adenoscan

Adenoscan is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5731296 Selective vasodilation by continuous adenosine infusion 24 Mar, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adenoscan's drug page


2. Ambisome

Ambisome is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5965156 Amphotericin B liposome preparation 12 Oct, 2016
(8 years ago)
Expired
US5874104 Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics 23 Feb, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ambisome's drug page


3. Astagraf Xl

Astagraf Xl is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6440458 Sustained release preparations 25 Mar, 2019
(5 years ago)
Expired
US6576259 Sustained release formulations containing tacrolimus 25 Mar, 2019
(5 years ago)
Expired
US6884433 Sustained release formulation containing tacrolimus 25 Mar, 2019
(5 years ago)
Expired
US8551522 Sustained-release formulation 25 Mar, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Astagraf Xl's drug page


4. Cresemba

Cresemba is protected by 8 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10206879
(Pediatric)
Active ingredient containing stabilised solid forms and method for the production thereof 14 Mar, 2028
(3 years from now)
Active
US10603280
(Pediatric)
Active ingredient containing stabilised solid medicinal forms and methods for the production thereof 14 Mar, 2028
(3 years from now)
Active
US10206879 Active ingredient containing stabilised solid forms and method for the production thereof 14 Sep, 2027
(2 years from now)
Active
US10603280 Active ingredient containing stabilised solid medicinal forms and methods for the production thereof 14 Sep, 2027
(2 years from now)
Active
US6812238
(Pediatric)
N-substituted carbamoyloxyalkyl-azolium derivatives 01 May, 2026
(1 year, 6 months from now)
Active
US10812238 Configurable reference signals 31 Oct, 2025
(1 year, 16 days from now)
Active
US6812238 N-substituted carbamoyloxyalkyl-azolium derivatives 31 Oct, 2025
(1 year, 16 days from now)
Active
US7459561 N-substituted carbamoyloxyalkyl-azolium derivatives 31 Oct, 2020
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cresemba's drug page


5. Izervay

Izervay is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11273171 Methods for treating or preventing ophthalmological conditions 11 Jul, 2034
(9 years from now)
Active
US11491176 Methods for treating or preventing ophthalmological conditions 11 Jul, 2034
(9 years from now)
Active
US12016875 Methods for treating or preventing ophthalmological conditions 11 Jul, 2034
(9 years from now)
Active
US8236773 Aptamer therapeutics useful in the treatment of complement-related disorders 11 Nov, 2026
(2 years from now)
Active
US10947544 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
(4 months from now)
Active
US7538211 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
(4 months from now)
Active
US7579456 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
(4 months from now)
Active
US7803931 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
(4 months from now)
Active
US9617546 Aptamer therapeutics useful in the treatment of complement-related disorders 14 Feb, 2025
(4 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Izervay's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Lexiscan

Lexiscan is protected by 19 patents, out of which 16 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8106183 Process for preparing an A2A-adenosine receptor agonist and its polymorphs 02 Feb, 2027
(2 years from now)
Active
US9085601 Process for preparing an A2A-adenosine receptor agonist and its polymorphs 02 Feb, 2027
(2 years from now)
Active
USRE47301 Process for preparing an A2A-adenosine receptor agonist and its polymorphs 02 Feb, 2027
(2 years from now)
Active
US6403567 N-pyrazole A2A adenosine receptor agonists 10 Apr, 2022
(2 years ago)
Expired
US6642210 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists 22 Jun, 2019
(5 years ago)
Expired
US7144872 N-pyrazole A2A receptor agonists 22 Jun, 2019
(5 years ago)
Expired
US7183264 N-pyrazole A2A receptor agonists 22 Jun, 2019
(5 years ago)
Expired
US7582617 Myocardial perfusion imaging method 22 Jun, 2019
(5 years ago)
Expired
US7655636 Use of A2A adenosine receptor agonists 22 Jun, 2019
(5 years ago)
Expired
US7655637 N-pyrazole A2A receptor agonists 22 Jun, 2019
(5 years ago)
Expired
US7683037 Myocardial perfusion imaging method 22 Jun, 2019
(5 years ago)
Expired
US8106029 Use of A2A adenosine receptor agonists 22 Jun, 2019
(5 years ago)
Expired
US8133879 Myocardial perfusion imaging methods and compositions 22 Jun, 2019
(5 years ago)
Expired
US8183226 Myocardial perfusion imaging method 22 Jun, 2019
(5 years ago)
Expired
US8470801 Myocardial perfusion imaging methods and compositions 22 Jun, 2019
(5 years ago)
Expired
US8536150 Methods of myocardial perfusion imaging 22 Jun, 2019
(5 years ago)
Expired
US9045519 N-pyrazole A2A receptor agonists 22 Jun, 2019
(5 years ago)
Expired
US9289446 Myocardial perfusion imaging methods and compositions 22 Jun, 2019
(5 years ago)
Expired
USRE47351 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists 22 Jun, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lexiscan's drug page


7. Mycamine

Mycamine is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6774104
(Pediatric)
Stabilized pharmaceutical composition in lyophilized form 08 Jul, 2021
(3 years ago)
Expired
US6774104 Stabilized pharmaceutical composition in lyophilized form 08 Jan, 2021
(3 years ago)
Expired
US6107458 Cyclic hexapeptides having antibiotic activity 16 Mar, 2019
(5 years ago)
Expired
US6265536 Cyclic hexapeptides having antibiotic activity 29 Sep, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mycamine's drug page


8. Veozah

Veozah is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10836768 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists 28 Mar, 2034
(9 years from now)
Active
US9422299 Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists 28 Mar, 2034
(9 years from now)
Active
US9987274 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists 28 Mar, 2034
(9 years from now)
Active
US8871761 NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders 04 Apr, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veozah's drug page


9. Vesicare

Vesicare is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6017927
(Pediatric)
Quinuclidine derivatives and medicinal composition thereof 19 May, 2019
(5 years ago)
Expired
US6017927 Quinuclidine derivatives and medicinal composition thereof 19 Nov, 2018
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vesicare's drug page


10. Vesicare Ls

Vesicare Ls is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9918970 Pharmaceutical composition comprising solifenacin 18 May, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vesicare Ls's drug page


11. Xospata

Xospata is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10786500 Stable pharmaceutical composition for oral administration 01 Jul, 2036
(11 years from now)
Active
US11938130 Stable pharmaceutical composition for oral administration 01 Jul, 2036
(11 years from now)
Active
US11938131 Stable pharmaceutical composition for oral administration 01 Jul, 2036
(11 years from now)
Active
US11938132 Stable pharmaceutical composition for oral administration 01 Jul, 2036
(11 years from now)
Active
US11938133 Stable pharmaceutical composition for oral administration 01 Jul, 2036
(11 years from now)
Active
US11944620 Stable pharmaceutical composition for oral administration 01 Jul, 2036
(11 years from now)
Active
US8969336 Diamino heterocyclic carboxamide compound 28 Nov, 2032
(8 years from now)
Active
US9487491 Diamino heterocyclic carboxamide compound 28 Jul, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xospata's drug page


12. Xtandi

Xtandi is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11839689 Formulations of enzalutamide 11 Sep, 2033
(8 years from now)
Active
US7709517 Diarylhydantoin compounds 13 Aug, 2027
(2 years from now)
Active
US8183274 Treatment of hyperproliferative disorders with diarylhydantoin compounds 24 Aug, 2026
(1 year, 10 months from now)
Active
US9126941 Treatment of hyperproliferative disorders with diarylhydantoin compounds 15 May, 2026
(1 year, 6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xtandi's drug page


Astellas News

Lilly's Focus on Direct-to-Consumer Marketing for Obesity, Job Cuts, and Interest in Eye Conditions - BioSpace

04 Sep, 2024

Astellas and Pfizer file lawsuit to prevent generic versions of profitable Xtandi medication

02 Aug, 2024

Bayer prepares competitor to Astellas menopause drug using fresh data

19 Mar, 2024

Pfizer and Astellas aim to obtain revised authorization from EMA for Padcev in combination with Keytruda.

29 Jan, 2024

See More